Immupharma PLC still confident on Lupuzor's future

ImmuPharma PLC (LON:IMM) CEO Dimitri Dimitriou and chairman Tim McCarthy discuss with Proactive Investors the top-line results from their phase III trial of the drug Lupuzor.

The data revealed Lupuzor was more effective than the placebo (52.5% versus 44.6%) however because the response rate for those taking the non-active medication plus the “standard of care” was so high the end-point of the study was not achieved. That 'end-point' was a statistically significant beneficial impact from Lupuzor.